Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future prospects for oncolytic therapy.

Frank McCormick1

  • 1University of California San Francisco, Cancer Research Institute, CA 94115, USA.

Oncogene
|November 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NF1 and SPRED1/2 cooperate through RAS-MAPK-independent functions.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS<sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibition.

bioRxiv : the preprint server for biology·2026
Same author

Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass.

The Biochemical journal·2026
Same author

Dashboard Knee: Injury Mechanisms, Diagnostic Challenges, and Treatment Outcomes.

Cureus·2026
Same author

The heart of the matter: a personal view of Fred Wittinghofer's contributions to RAS biology and drug design.

Biological chemistry·2026
Same author

Disulfide tethering reveals cryptic pockets in oncogenic KRAS.

Communications chemistry·2026
Same journal

DNA methylation-mediated silencing of STAT5A drives breast cancer metastasis via dual regulation of EMT and immunosuppressive microenvironment.

Oncogene·2026
Same journal

LncRNA IRENA promotes peripheral T-cell lymphoma progression through scaffolding ARHGEF1 and FMNL1 to modulate RHOA GTPase/MAPK signaling.

Oncogene·2026
Same journal

A novel circSLIT2-encoded SLIT2 isoform suppresses neural invasion in gastric cancer.

Oncogene·2026
Same journal

The miR-302 family suppresses tumor growth in tongue squamous cell carcinoma by directly targeting P65.

Oncogene·2026
Same journal

MOV10 suppresses circRNA biogenesis by disrupting reverse complementary matches structure to drive hepatocarcinogenesis.

Oncogene·2026
Same journal

HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer.

Oncogene·2026
See all related articles

Engineered oncolytic viruses show promise for cancer treatment, demonstrating safety and efficacy in early trials. Overcoming challenges in systemic delivery and immune response is key to their mainstream clinical use.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Oncolytic viruses are engineered to selectively replicate within cancer cells.
  • Several oncolytic virus candidates have advanced to clinical trials, showing good safety profiles and initial efficacy.

Purpose of the Study:

  • To review the principles and progress of oncolytic virus engineering for cancer therapy.
  • To identify barriers to systemic application and suggest future research directions.

Main Methods:

  • Review of innovative principles in oncolytic virus design.
  • Analysis of clinical trial data regarding safety and efficacy.
  • Discussion of strategies to overcome systemic delivery and immune response challenges.

Main Results:

Related Experiment Videos

  • Engineered oncolytic viruses exhibit selective replication in tumors.
  • Clinical trials indicate favorable safety and preliminary efficacy.
  • Systemic function remains a challenge requiring further research.

Conclusions:

  • Oncolytic viruses hold significant potential as a cancer treatment modality.
  • Overcoming immune suppression and improving tumor targeting are crucial for widespread adoption.
  • Further research is needed to fully realize the potential of oncolytic virotherapy in clinical oncology.